X-ray sorting screened out about 20% of lower-grade material in a small test, potentially extending mine life.

Brazil's Supreme Federal Court rejected a petition to halt activities at Brazil Potash Corp.'s Autazes Project. The decision upholds previous favorable rulings from the federal Court of Appeals. The company plans to continue developing the project, which aims to supply 20% of Brazil's potash demand.

HSBC upgraded Labcorp (LH) to Buy from Hold, raising its price target to $410 from $330, citing the company's M&A strategy and diagnostics business momentum.

Pegasystems Inc. (PEGA) secured a 10-year U.S. Army contract worth up to $419M to modernize operations. The company did not provide prior-period comparisons or expected revenue details.

Gilead Sciences (GILD) reported that 52.3% of participants in the Phase 3 IDEAL study achieved ALP normalization after one month of Livdelzi treatment, compared to 6.5% on placebo. The response was sustained through Week 52. Serious adverse events were lower in the treatment group (3.1%) than in the placebo group (12.9%).

Altimmune (ALT) announced that data from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder (AUD) will be presented at The Liver Meeting 2026. The trial met primary and secondary endpoints, showing a significant reduction in heavy drinking days. The company plans an End-of-Phase 2 meeting with the FDA in December. Pemvidutide has Fast Track and Breakthrough Therapy designations for AUD and MASH.

Madrigal Pharmaceuticals (MDGL) reported real-world study results for Rezdiffra at AASLD. Up to 93% of patients showed liver stiffness improvement, 72% remained on treatment for a year, and safety findings aligned with trials. Improvements were seen across diverse patient groups, including those using GLP-1 therapies.